- Home
- PRPO vs CMND Comparison
PRPO vs CMND Comparison
Compare PRPO & CMND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PRPO
- CMND
- Stock Information
- Founded
- PRPO N/A
- CMND 2017
- Country
- PRPO United States
- CMND Canada
- Employees
- PRPO N/A
- CMND N/A
- Industry
- PRPO Biotechnology: Laboratory Analytical Instruments
- CMND Biotechnology: Pharmaceutical Preparations
- Sector
- PRPO Industrials
- CMND Health Care
- Exchange
- PRPO Nasdaq
- CMND Nasdaq
- Market Cap
- PRPO N/A
- CMND 4.8M
- IPO Year
- PRPO N/A
- CMND N/A
- Fundamental
- Price
- PRPO $16.27
- CMND $1.01
- Analyst Decision
- PRPO
- CMND
- Analyst Count
- PRPO 0
- CMND 0
- Target Price
- PRPO N/A
- CMND N/A
- AVG Volume (30 Days)
- PRPO 13.9K
- CMND 2.2M
- Earning Date
- PRPO 08-12-2025
- CMND 06-12-2025
- Dividend Yield
- PRPO N/A
- CMND N/A
- EPS Growth
- PRPO N/A
- CMND N/A
- EPS
- PRPO N/A
- CMND N/A
- Revenue
- PRPO $20,029,000.00
- CMND N/A
- Revenue This Year
- PRPO N/A
- CMND N/A
- Revenue Next Year
- PRPO N/A
- CMND N/A
- P/E Ratio
- PRPO N/A
- CMND N/A
- Revenue Growth
- PRPO 26.67
- CMND N/A
- 52 Week Low
- PRPO $3.90
- CMND $0.80
- 52 Week High
- PRPO $16.50
- CMND $2.30
- Technical
- Relative Strength Index (RSI)
- PRPO 82.13
- CMND 55.05
- Support Level
- PRPO $10.60
- CMND $0.94
- Resistance Level
- PRPO $11.70
- CMND $1.31
- Average True Range (ATR)
- PRPO 0.86
- CMND 0.08
- MACD
- PRPO 0.43
- CMND 0.02
- Stochastic Oscillator
- PRPO 93.06
- CMND 33.35
About CMND Clearmind Medicine Inc.
Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.